Real-World Effectiveness of Mavacamten in Canada
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT06338202
- Status
- Completed
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mavacamten — DRUGAs detailed in the product label
Study Details
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.
Key Dates
- Start date
- Jun 24, 2024
- Status verified
- Nov 2025
- Primary completion
- Nov 12, 2024
- Completion
- Dec 19, 2024
Study Design
- Enrollment
- 115 participants (actual)
Arms
- Arm: Patients treated with mavacamtenPatients with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care
Primary Outcome Measure
Change in New York Heart Association (NYHA) functional class following mavacamten treatment initiation [ Time Frame: Up to 1.5 years ]